Viatris Focuses On Being First In Race For Eylea Biosimilar
‘We Will Be Filing Within This Year’ Indicates Viatris President Malik
Viatris has reiterated the strength of its biosimilars and complex generics pipeline, highlighting opportunities including biosimilar Eylea, Botox and once-a-month Copaxone.
You may also be interested in...
Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.
Teva was drawn into the conversation around generic price erosion, especially in the US and Europe, after Sandoz singled out the unfavorable effect during a lackluster Q1.
Recently-formed Viatris is looking to build on the success of several high-margin complex generics launches, including versions of Advair and Copaxone, by developing further candidates, including rivals to Novo Nordisk’s Rybelsus (semaglutide) and Victoza (liraglutide).